| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | -100.0% |
| R&D Expense | $1.6M | — | +41.1% |
| SG&A Expense | $2.3M | — | +29.5% |
| Operating Income | -$3.9M | — | -35.4% |
| Net Income | -$2.6M | — | +1.4% |
| EPS (Basic) | -$0.04 | — | +60.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $3.8M | -35.1% | -29.0% |
| Short-term Investments | $17.3M | +19.3% | — |
| Current Assets | $21.3M | +2.1% | +245.5% |
| Total Assets | $30.2M | +1.5% | +101.1% |
| Current Liabilities | $4.0M | +5.7% | +102.4% |
| Total Liabilities | $11.7M | -7.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$3.4M | — | +2.0% |
| Investing Cash Flow | -$2.7M | — | — |
| Financing Cash Flow | $4.0M | — | — |
| +24.3% |
| Stockholders' Equity | $18.5M | +8.5% | +230.0% |